Vita Life Sciences Limited provided group earnings guidance for the second half and full year ending December 2012. For the period, the group expects revenue to continue its momentum with growth in the second half of the year being similar to the first half. NPAT for the second half is anticipated to be similar to the first half. Based on the group's management accounts to October and its forecast for November and December 2012: Sales revenue is forecast to be $29.0 million to $30.0 million, or approximately 20% higher than the year to December 31, 2011. Profit before tax to be approximately 18% - 20% higher than that reported for the six months to June 2012.

For the year, the company expects profit before tax to be approximately $2.3 million, or 65% higher than the year to December 2011.

The company's Directors expect to declare a fully franked final dividend of 0.5 cent per share payable in April 2013.